Should I buy or sell Reviva Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks .

What is Reviva Pharmaceuticals' stock price target for 2024?

4 Wall Street analysts have issued 1-year price targets for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's share price to reach $16.75 in the next year. This suggests a possible upside of 454.6% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts .

How have RVPH shares performed in 2024?

Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of 2024. Since then, RVPH shares have decreased by 41.4% and is now trading at $3.02. View the best growth stocks for 2024 here .

Are investors shorting Reviva Pharmaceuticals?

Reviva Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,060,000 shares, an increase of 62.9% from the March 15th total of 650,700 shares. Based on an average daily volume of 331,800 shares, the short-interest ratio is presently 3.2 days. View Reviva Pharmaceuticals' Short Interest .

When is Reviva Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RVPH earnings forecast .

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.11.

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free RVPH Stock Alerts

$3.02

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $2.95
▼
$3.08
50-Day Range: $2.76
▼
$4.70
52-Week Range: $2.67
▼
$9.25

Volume: 139,500 shs
Average Volume: 318,480 shs
Market Capitalization: $84.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.75

Get Reviva Pharmaceuticals alerts:

Reviva Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 454.6% Upside
$16.75 Price Target
Short Interest: Healthy
3.80% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.42
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.92) to ($0.76) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

355th out of 911 stocks

Pharmaceutical Preparations Industry

152nd out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Reviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.80% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Reviva Pharmaceuticals has recently increased by 62.90%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Reviva Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reviva Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RVPH.

3.0

News and Social Media Coverage

News Sentiment
Reviva Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
5 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
MarketBeat Follows
8 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.92) to ($0.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reviva Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reviva Pharmaceuticals is -1.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reviva Pharmaceuticals has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

RVPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVPH Stock News Headlines

April 17, 2024 | americanbankingnews.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Given Speculative Buy Rating at Benchmark

April 15, 2024 | msn.com

RVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Data

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

April 15, 2024 | investorplace.com

RVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023

April 15, 2024 | finanznachrichten.de

Reviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

April 15, 2024 | finanznachrichten.de

Reviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

April 15, 2024 | globenewswire.com

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

April 15, 2024 | globenewswire.com

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

April 19, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 28, 2024 | finance.yahoo.com

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

March 28, 2024 | globenewswire.com

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

March 27, 2024 | finance.yahoo.com

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

March 25, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic Promise

March 14, 2024 | finance.yahoo.com

RVPH Mar 2024 3.000 put

March 11, 2024 | globenewswire.com

Reviva to Present at the UBS Virtual CNS Day

March 7, 2024 | globenewswire.com

Reviva to Present at the 36th Annual ROTH Conference

March 3, 2024 | finance.yahoo.com

RVPH Mar 2024 3.500 call

February 29, 2024 | finance.yahoo.com

RVPH Jan 2026 5.500 call

February 27, 2024 | finance.yahoo.com

RVPH Apr 2024 12.500 call

February 23, 2024 | ca.finance.yahoo.com

RVPH Mar 2024 4.500 put

February 22, 2024 | benzinga.com

Reviva Pharmaceuticals Stock (NASDAQ:RVPH), Short Interest Report

February 20, 2024 | finance.yahoo.com

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

February 20, 2024 | globenewswire.com

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

February 17, 2024 | finance.yahoo.com

RVPH Mar 2024 3.000 call

February 17, 2024 | finance.yahoo.com

RVPH Mar 2024 5.500 put

January 25, 2024 | finance.yahoo.com

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

January 17, 2024 | ca.finance.yahoo.com

RVPH Jan 2025 7.500 call

See More Headlines

Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RVPH
CUSIP: N/A
CIK: 1742927
Web: www.revivapharma.com
Phone: (408) 501-8881
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.75
High Stock Price Target: $20.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +454.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,344.46%
Return on Assets: -307.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.41
Quick Ratio: 0.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 5.03

Miscellaneous

Outstanding Shares: 27,920,000
Free Float: 19,032,000
Market Cap: $84.32 million
Optionable: Optionable
Beta: -0.02

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Laxminarayan Bhat Ph.D. (Age 59)
Founder, CEO, President & Director
Comp: $560k
Mr. Narayan Prabhu (Age 52)
Chief Financial Officer
Comp: $412.5k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RVPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings or view top-rated stocks.
What is Reviva Pharmaceuticals' stock price target for 2024?: 4 Wall Street analysts have issued 1-year price targets for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they expect the company's share price to reach $16.75 in the next year. This suggests a possible upside of 454.6% from the stock's current price.
View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts.
How have RVPH shares performed in 2024?: Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of 2024. Since then, RVPH shares have decreased by 41.4% and is now trading at $3.02.
View the best growth stocks for 2024 here.
Are investors shorting Reviva Pharmaceuticals?: Reviva Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,060,000 shares, an increase of 62.9% from the March 15th total of 650,700 shares. Based on an average daily volume of 331,800 shares, the short-interest ratio is presently 3.2 days.
View Reviva Pharmaceuticals' Short Interest.

When is Reviva Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RVPH earnings forecast.
How were Reviva Pharmaceuticals' earnings last quarter?: Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) posted its quarterly earnings results on Monday, November, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.11.
How do I buy shares of Reviva Pharmaceuticals?: Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVPH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial